Zymeworks Inc. Common Shares (ZYME): Price and Financial Metrics
ZYME Price/Volume Stats
| Current price | $12.02 | 52-week high | $12.14 |
| Prev. close | $11.71 | 52-week low | $6.01 |
| Day low | $11.58 | Volume | 314,000 |
| Day high | $12.14 | Avg. volume | 551,664 |
| 50-day MA | $10.45 | Dividend yield | N/A |
| 200-day MA | $8.43 | Market Cap | 841.42M |
ZYME Stock Price Chart Interactive Chart >
ZYME POWR Grades
- Value is the dimension where ZYME ranks best; there it ranks ahead of 99.13% of US stocks.
- The strongest trend for ZYME is in Quality, which has been heading up over the past 26 weeks.
- ZYME's current lowest rank is in the Growth metric (where it is better than 10.44% of US stocks).
ZYME Stock Summary
- ZYME's current price/earnings ratio is 3.64, which is higher than only 2.87% of US stocks with positive earnings.
- Over the past twelve months, ZYME has reported earnings growth of -197.64%, putting it ahead of merely 6.58% of US stocks in our set.
- Revenue growth over the past 12 months for ZYMEWORKS INC comes in at 1,445.86%, a number that bests 99.5% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ZYME, based on their financial statements, market capitalization, and price volatility, are VCNX, WVE, IKT, FDMT, and SPRO.
- Visit ZYME's SEC page to see the company's official filings. To visit the company's web site, go to www.zymeworks.com.
ZYME Valuation Summary
- ZYME's price/earnings ratio is 3.5; this is 87.99% lower than that of the median Healthcare stock.
- Over the past 81 months, ZYME's EV/EBIT ratio has gone up 11.4.
Below are key valuation metrics over time for ZYME.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZYME | 2023-12-29 | 1.6 | 1.7 | 3.5 | 3.0 |
| ZYME | 2023-12-28 | 1.6 | 1.8 | 3.6 | 3.1 |
| ZYME | 2023-12-27 | 1.6 | 1.8 | 3.7 | 3.1 |
| ZYME | 2023-12-26 | 1.6 | 1.8 | 3.6 | 3.1 |
| ZYME | 2023-12-22 | 1.5 | 1.6 | 3.4 | 2.8 |
| ZYME | 2023-12-21 | 1.4 | 1.5 | 3.2 | 2.7 |
ZYME Growth Metrics
- Its year over year cash and equivalents growth rate is now at -1.58%.
- Its 4 year net income to common stockholders growth rate is now at -1465.75%.
- The 2 year net cashflow from operations growth rate now stands at -111.2%.
The table below shows ZYME's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 29.859 | -233.76 | -224.242 |
| 2022-06-30 | 31.623 | -211.532 | -236.975 |
| 2022-03-31 | 27.952 | -207.06 | -239.878 |
| 2021-12-31 | 26.68 | -192.451 | -211.843 |
| 2021-09-30 | 22.49 | -189.845 | -210.584 |
| 2021-06-30 | 20.738 | -155.115 | -222.567 |
ZYME's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZYME has a Quality Grade of D, ranking ahead of 18.34% of graded US stocks.
- ZYME's asset turnover comes in at 0.047 -- ranking 324th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ZYME's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.047 | 1 | -1.423 |
| 2021-06-30 | 0.040 | 1 | -1.267 |
| 2021-03-31 | 0.057 | 1 | -0.902 |
| 2020-12-31 | 0.066 | 1 | -0.661 |
| 2020-09-30 | 0.046 | 1 | -0.832 |
| 2020-06-30 | 0.060 | 1 | -0.772 |
Zymeworks Inc. Common Shares (ZYME) Company Bio
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company was founded in 2003 and is based in Vancouver, BC.
Latest ZYME News From Around the Web
Below are the latest news stories about ZYMEWORKS INC that investors may wish to consider to help them evaluate ZYME as an investment opportunity.
Small-Cap Sensations: 3 Stocks Predicted for Massive Growth in 2024These three small-cap stocks have massive return potential in 2024 and beyond, according to analyst forecasts and broader industry trends. |
Zymeworks Announces $50 Million Private Placement to EcoR1 CapitalProceeds expected to extend cash runway into H2 2027VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par v |
From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a FortuneAre you looking for small-cap stocks to get rich? |
Want to Turn Spare Change Into $1,000? Buy These 3 Stocks NowThree high conviction stocks seem perfect for opportunistic investors and could quickly transform spare change into four-figure returns. |
Zymeworks Added to Nasdaq Biotechnology IndexVANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market th |
ZYME Price Returns
| 1-mo | 21.66% |
| 3-mo | 46.23% |
| 6-mo | 50.82% |
| 1-year | 39.44% |
| 3-year | -70.78% |
| 5-year | -20.19% |
| YTD | 15.69% |
| 2023 | 32.19% |
| 2022 | -52.04% |
| 2021 | -65.32% |
| 2020 | 3.96% |
| 2019 | 209.67% |
Continue Researching ZYME
Here are a few links from around the web to help you further your research on Zymeworks Inc's stock as an investment opportunity:Zymeworks Inc (ZYME) Stock Price | Nasdaq
Zymeworks Inc (ZYME) Stock Quote, History and News - Yahoo Finance
Zymeworks Inc (ZYME) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...